Hunan Dajiaweikang Pharmaceutical IndustryLtd Past Earnings Performance
Past criteria checks 4/6
Hunan Dajiaweikang Pharmaceutical IndustryLtd's earnings have been declining at an average annual rate of -21.5%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 18.3% per year. Hunan Dajiaweikang Pharmaceutical IndustryLtd's return on equity is 3.1%, and it has net margins of 0.9%.
Key information
-21.5%
Earnings growth rate
-29.9%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 18.3% |
| Return on equity | 3.1% |
| Net Margin | 0.9% |
| Next Earnings Update | 21 Apr 2025 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Massive 41% Price Jump
Oct 08
Optimistic Investors Push Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Shares Up 30% But Growth Is Lacking
May 09Market Might Still Lack Some Conviction On Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Even After 31% Share Price Boost
Mar 08Revenue & Expenses Breakdown
How Hunan Dajiaweikang Pharmaceutical IndustryLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,110 | 47 | 769 | 15 |
| 30 Jun 24 | 4,734 | 48 | 645 | 14 |
| 31 Mar 24 | 4,307 | 38 | 542 | 9 |
| 31 Dec 23 | 3,904 | 34 | 436 | 7 |
| 30 Sep 23 | 3,830 | 22 | 384 | 4 |
| 30 Jun 23 | 3,666 | 31 | 361 | 2 |
| 31 Mar 23 | 3,542 | 47 | 314 | 1 |
| 01 Jan 23 | 3,292 | 51 | 271 | 1 |
| 30 Sep 22 | 2,943 | 71 | 221 | 0 |
| 30 Jun 22 | 2,733 | 71 | 184 | 0 |
| 31 Mar 22 | 2,643 | 68 | 175 | 0 |
| 31 Dec 21 | 2,592 | 68 | 162 | 0 |
| 30 Sep 21 | 2,536 | 85 | 148 | 0 |
| 30 Jun 21 | 2,535 | 89 | 133 | 0 |
| 31 Mar 21 | 2,387 | 79 | 132 | 0 |
| 31 Dec 20 | 2,340 | 65 | 137 | 0 |
| 31 Dec 19 | 2,457 | 88 | 126 | 0 |
| 31 Dec 18 | 2,189 | 78 | 125 | 0 |
| 31 Dec 17 | 2,022 | 80 | 126 | 0 |
| 30 Jun 17 | 2,003 | 65 | 111 | 0 |
| 31 Mar 17 | 1,951 | 61 | 101 | 0 |
| 31 Dec 16 | 1,899 | 58 | 91 | 0 |
| 30 Sep 16 | 1,787 | 54 | 78 | 0 |
| 30 Jun 16 | 1,674 | 50 | 66 | 0 |
| 31 Mar 16 | 1,605 | 49 | 63 | 0 |
| 31 Dec 15 | 1,537 | 47 | 61 | 0 |
| 30 Sep 15 | 1,879 | 44 | 78 | 0 |
| 30 Jun 15 | 2,221 | 40 | 95 | 0 |
| 31 Mar 15 | 1,905 | 31 | 82 | 0 |
| 31 Dec 14 | 1,588 | 21 | 69 | 0 |
Quality Earnings: 301126 has high quality earnings.
Growing Profit Margin: 301126's current net profit margins (0.9%) are higher than last year (0.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301126's earnings have declined by 21.5% per year over the past 5 years.
Accelerating Growth: 301126's earnings growth over the past year (113.1%) exceeds its 5-year average (-21.5% per year).
Earnings vs Industry: 301126 earnings growth over the past year (113.1%) exceeded the Healthcare industry -5.7%.
Return on Equity
High ROE: 301126's Return on Equity (3.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 17:57 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|